Literature DB >> 8690833

Pharmacokinetics of clozapine and risperidone: a review of recent literature.

M J Byerly1, C L DeVane.   

Abstract

The current literature describing the pharmacokinetics of the atypical antipsychotics clozapine and risperidone is reviewed, and discussion on the clinical significance of these data is presented. These drugs are well absorbed when taken orally but are poorly bioavailable because of presystemic elimination. They are highly cleared by hepatic metabolism involving specific P450 isozymes. Risperidone elimination produces a potent active metabolite. Neither of the drugs has received extensive study related to drug-drug interactions, but several are potentially important because a purported therapeutic plasma concentration range is proposed for clozapine and a possible curvilinear dose response relationship has been reported for risperidone. The current clinical pharmacokinetic database for these atypical antipsychotics suggests that much can be learned with additional study that would be of value in individualizing their dosage regimens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690833     DOI: 10.1097/00004714-199604000-00010

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  14 in total

Review 1.  Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia.

Authors:  N Bhana; C M Spencer
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

Review 2.  Interactions between the cytochrome P450 system and the second-generation antipsychotics.

Authors:  Trevor I Prior; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2003-03       Impact factor: 6.186

Review 3.  Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.

Authors:  W W Fleischhacker; M Hummer
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

4.  A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics.

Authors:  Gianluigi Tanda; Valentina Valentini; Maria Antonietta De Luca; Valentina Perra; Gian Pietro Serra; Gaetano Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  2014-10-28       Impact factor: 4.530

Review 5.  Biotransformation of post-clozapine antipsychotics: pharmacological implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 6.  Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder.

Authors:  Antona Wagstaff; Caroline Perry
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 7.  Risperidone augmentation of clozapine: a critical review.

Authors:  Vassilis P Kontaxakis; Panayotis P Ferentinos; Beata J Havaki-Kontaxaki; Konstantinos G Paplos; Dimitra A Pappa; George N Christodoulou
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08-08       Impact factor: 5.270

8.  Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.

Authors:  SuJean Choi; Briana DiSilvio; JayLynn Unangst; John D Fernstrom
Journal:  Life Sci       Date:  2007-08-17       Impact factor: 5.037

9.  Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver.

Authors:  Johan Fernø; Audun O Vik-Mo; Goran Jassim; Bjarte Håvik; Kjetil Berge; Silje Skrede; Oddrun A Gudbrandsen; Jo Waage; Niclas Lunder; Sverre Mørk; Rolf K Berge; Hugo A Jørgensen; Vidar M Steen
Journal:  Psychopharmacology (Berl)       Date:  2008-10-30       Impact factor: 4.530

10.  Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.

Authors:  G Schaber; I Stevens; H J Gaertner; K Dietz; U Breyer-Pfaff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.